Defining safe thresholds for risk-adapted surveillance after liver transplantation for hepatocellular carcinoma
Digestive and Liver Disease · 2026
DOI: 10.1016/j.dld.2025.12.021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Digestive and Liver Disease, 2026. Verfasst von Pedro Robson Costa Passos und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center of Research and Drug Development (NPDM), Federal University of Ceara, Fortaleza, Ceara, Brazil; Department of Surgery, Federal University of C…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Transplantation, Liver Neoplasms, Neoplasm Recurrence, Local. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) is a major concern, but it is unclear whether existing models can safely "rule out" patients from intensive imaging strategies. METHODS: We retrospectively studied 493 LT recipients transplanted for HCC (2002-2023). Competing-risk Fine-Gray regression with bootstrap stability selection was used to derive an illustrative score and compared with established models. Rule-out performance was evaluated by 5-year cumulative incidence. Decision curve analysis (DCA) and surveillance simulations quantified trade-offs between CT scans saved and recurrences missed under reduced protocols. RESULTS: Our model identified total tumor diameter, microvascular invasion, satellite nodules, and log(AFP) as stable predictors. DCA showed all models outperformed uniform surveillance only when 5-year recurrence exceeded 4%, with 7.5% as the upper acceptable threshold. Within this range, low-risk groups across models had 5-year recurrence risks of 2.5-5.7%. Reduced-intensity strategies could save 160-856 CTs per 100 patients while missing ≤1 recurrence with semiannual or annual two-year protocols. Cost-benefit analysis supported 4-7.5% as the optimal threshold. False negatives were uncommon (n = 13), with only two patients misclassified by all models. CONCLUSIONS: Widely used models can identify patients suitable for reduced surveillance, though none delineated a true "no-screening" group.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center of Research and Drug Development (NPDM), Federal University of Ceara, Fortaleza, Ceara, Brazil; Department of Surgery, Federal University of Ceara, Fortaleza, Ceara, Brazil. Electronic address: pedropassos@alu.uf…
- Department of Surgery, Federal University of Ceara, Fortaleza, Ceara, Brazil.
- Liver Transplantation Unit, Walter Cantídio University Hospital, Fortaleza, Ceara, Brazil.
- Translational Gastroenterology and Liver Unit, University of Oxford, Oxford, UK.
- Department of Surgery, Federal University of Ceara, Fortaleza, Ceara, Brazil; Liver Transplantation Unit, Walter Cantídio University Hospital, Fortaleza, Ceara, Brazil.
Zitieren
APA
Passos, P. R. C., Viana, D. D. A., de Araújo Chollet, G. G., Magalhães, A. E. B., de Lima, C. A., Neto, B. A., Motta, R., Costa, P. E. G., Hyppolito, E. B., Rego Coelho, G., & Garcia, J. H. P. (2026). Defining safe thresholds for risk-adapted surveillance after liver transplantation for hepatocellular carcinoma. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2025.12.021
Vancouver
Passos PRC, Viana DDA, de Araújo Chollet GG, Magalhães AEB, de Lima CA, Neto BA, et al. Defining safe thresholds for risk-adapted surveillance after liver transplantation for hepatocellular carcinoma. Digestive and Liver Disease. 2026. doi:10.1016/j.dld.2025.12.021
BibTeX
@article{Passos2026,
author = {Passos, Pedro Robson Costa and Viana, Danilo Dias Avancini and de Araújo Chollet, Gabriel Gomes and Magalhães, Angel Evangelista Barroso and de Lima, Clebia Azevedo and Neto, Bartolomeu Alves and Motta, Rodrigo and Costa, Paulo Everton Garcia and Hyppolito, Elodie Bomfim and Rego Coelho, Gustavo and Garcia, José Huygens Parente},
title = {Defining safe thresholds for risk-adapted surveillance after liver transplantation for hepatocellular carcinoma},
journal = {Digestive and Liver Disease},
year = {2026},
doi = {10.1016/j.dld.2025.12.021}
}
EUVIMED